Company news
Bioasis Technologies Inc. (OTC:BIOAF) news
Bioasis Technologies Inc. news releases on 6ix. Latest, Jun 29, 2020: Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance
Press releases — page 2
Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance
June 29, 2020
Bioasis Announces Conversion of Debenture Interest Into Equity
June 24, 2020
Bioasis Announces Analyst Coverage Initiated by Edison Group
June 17, 2020
Bioasis Completes Redemption of 15% Unsecured Debentures With Unanimous Debentureholder Approval
April 6, 2020
Bioasis Announces Proposed Redemption of 15% Unsecured Debentures
March 6, 2020
Bioasis Technologies Announces the Appointment of Dr. May Orfali to the Position of Consultant Chief Medical Officer
March 4, 2020
Growth Company Investor Presentations Now Available for On-Demand Viewing
February 24, 2020
Bioasis to Present at the OTC Markets 2020 Virtual Investor Conference
February 19, 2020
Live Investor Conference & Webinar: Growth Company CEOs Present February 20th
February 14, 2020
Bioasis to Present at the 22nd Annual BIO CEO Investor Conference and the OTC Markets 2020 Virtual Investor Conference
February 6, 2020
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2019
January 29, 2020
Bioasis Completes Bridge Financing Transaction
December 23, 2019
Bioasis Announces Bridge Financing
December 16, 2019
Bioasis Appoints Consultant Chief Medical Officer and Nominates Medical Oncology Advisory Board
December 4, 2019
Bioasis to Host Annual General Meeting Webcast on December 5, 2019
November 27, 2019
Bioasis Announces Director Resignation
November 25, 2019
Bioasis Announces Issuance of Japanese Patent Relating to xB3™ Platform Technology for The Delivery of Therapeutic Agents Across The Blood-Brain Barrier
November 14, 2019
Bioasis Completes Financing Transactions
November 8, 2019
Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending August 31, 2019
October 25, 2019
Bioasis Announces Proposed Private Placement
September 23, 2019
Bioasis Announces Allowance of Patent Application in Japan Relating to xB3 Platform Technology for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier
September 11, 2019
Bioasis Announces Registration and Grant Notice of Patent Application in China Relating to xB3 Platform Technology for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier
August 21, 2019
Bioasis Strengthens Senior Management Team with Appointment of Caroline Dircks, Ph.D. as Chief Operating Officer
August 15, 2019
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31, 2019
July 26, 2019
Bioasis Announces FDA Response to Pre-IND Submission
June 25, 2019
Bioasis Announces Allowances of Patent Applications in the U.S. and Europe Relating to xB3 Platform Technology and Key Therapeutic Indications
June 24, 2019
Bioasis Appoints Mario Saltarelli as Non-Executive Director of the Board of Directors
May 30, 2019
Bioasis Announces Closing of Previously Disclosed Private Placement
May 21, 2019
Bioasis Announces Private Placement
May 6, 2019
Bioasis Technologies Inc. Announces Warrant Extension
March 25, 2019
Bioasis Appoints Dr. Deborah Rathjen as President & Chief Executive Officer
March 11, 2019
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2018
January 29, 2019
Bioasis Announces the Appointment of Christine Antalik as Chief Financial Officer
January 9, 2019
Bioasis Announces Agreement With Leading Pharmaceutical Company for Pre-Clinical Research Using the xB3 Platform Technology
January 7, 2019
Bioasis to Present at Investor & Industry Conferences in January 2019
December 13, 2018
Bioasis Appoints Dr. Deborah A. Rathjen as Executive Chair of the Board of Directors
December 10, 2018
Bioasis Announces Voting Results for 2018 Annual and Special Meeting
November 26, 2018
Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with Lead Investigational Candidate xB3-001TM
November 20, 2018
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2018
October 30, 2018
Bioasis Announces xB3 ™ Platform Technology Licensing Agreement with Prothena
October 29, 2018
Bioasis Announces Investor Relations Service Agreement with Stern IR
October 4, 2018
Aeromics, Inc. Appoints Pharmaceutical and Biotech Veterans Mark Day, Ph.D. and Thomas Zindrick, J.D. to Its Board of Directors
August 16, 2018
Bioasis Announces Closing of Previously Disclosed Private Placement
August 13, 2018
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31, 2018
July 30, 2018
Bioasis Welcomes John E. Curran & David M. Wurzer to the Company’s Board of Directors
July 27, 2018
Bioasis Announces Positive Results from a Microdialysis Study Showing Lead Investigational Candidate xB3 ™-001 Increased Brain Activity
July 25, 2018
Bioasis Announces Non-Brokered Private Placement
July 15, 2018
Bioasis Announces Non-Brokered Private Placement
July 16, 2018
Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis’ Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic
July 11, 2018
Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O’Connor
June 12, 2018